116 related articles for article (PubMed ID: 15946492)
61. [Expression of MMP-9 and CD34 in papillary thyroid carcinomas].
Zhang HB; Wei QY
Hunan Yi Ke Da Xue Xue Bao; 2003 Aug; 28(4):427-8. PubMed ID: 14653139
[No Abstract] [Full Text] [Related]
62. [Expression of matrix metalloproteinase-2,9 in hypopharyngeal carcinoma and its relationship with lymphatic metastasis].
Li Q; Li X; Yao L
Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2004 Jun; 18(6):324-6. PubMed ID: 15354768
[TBL] [Abstract][Full Text] [Related]
63. Papillary thyroid carcinoma metastasis to the parapharyngeal space.
Aygenc E; Kaymakci M; Karaca C; Ozdem C
Eur Arch Otorhinolaryngol; 2002 Jul; 259(6):322-4. PubMed ID: 12115081
[TBL] [Abstract][Full Text] [Related]
64. [Vascular invasion, lymph node metastasis and extraglandular extension of well-differentiated carcinoma of the thyroid].
Hosoya T; Sakamoto A; Sakurai K; Kasai N
Gan No Rinsho; 1986 Jan; 32(1):23-6. PubMed ID: 3951124
[TBL] [Abstract][Full Text] [Related]
65. Expression of MMP-13 is associated with invasion and metastasis of papillary thyroid carcinoma.
Wang JR; Li XH; Gao XJ; An SC; Liu H; Liang J; Zhang K; Liu Z; Wang J; Chen Z; Sun W
Eur Rev Med Pharmacol Sci; 2013 Feb; 17(4):427-35. PubMed ID: 23467939
[TBL] [Abstract][Full Text] [Related]
66. Papillary and undifferentiated thyroid carcinoma presenting as a metastatic papillary serous effusion. A case report.
Hyman MP
Acta Cytol; 1979; 23(6):483-6. PubMed ID: 295166
[TBL] [Abstract][Full Text] [Related]
67. Enhanced activation of matrix metalloproteinase-9 correlates with the degree of papillary thyroid carcinoma infiltration.
Marecko I; Cvejic D; Selemetjev S; Paskas S; Tatic S; Paunovic I; Savin S
Croat Med J; 2014 Apr; 55(2):128-37. PubMed ID: 24778099
[TBL] [Abstract][Full Text] [Related]
68. [Correlation between thyroid-stimulating hormone-peroxiredoxin1 signaling pathway and invasion of papillary thyroid carcinoma].
Liu X; Gao M
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2009 Apr; 44(4):287-91. PubMed ID: 19558833
[TBL] [Abstract][Full Text] [Related]
69. Prognostic factors in papillary thyroid carcinoma and implications of large nodal metastasis.
Shaha AR
Surgery; 2004 Feb; 135(2):237-9. PubMed ID: 14739864
[No Abstract] [Full Text] [Related]
70. Serum Matrix metalloproteinase-9 (MMP-9) can help identify patients with papillary thyroid cancer at high risk of persistent disease: Value and limitations of a potential marker of neoplasia.
Dobrescu R; Picu C; Caragheorgheopol A; Manda D; Ioachim D; Goldstein A; Badiu C
Cancer Biomark; 2020; 29(3):337-346. PubMed ID: 32716342
[TBL] [Abstract][Full Text] [Related]
71. [Study of matrix metalloproteinase-2 and -9 in thyroid papillary cancer].
Maruyama S; Kawata R; Shimada T; Shinomiya T; Hirata Y; Yamamichi I; Murakami Y
Nihon Jibiinkoka Gakkai Kaiho; 2000 May; 103(5):499-505. PubMed ID: 10853337
[TBL] [Abstract][Full Text] [Related]
72. Serum Level of Matrix Metalloproteinase-2 and -9 in Patients with Laryngeal Squamous Cell Carcinoma and Clinical Significance.
Lotfi A; Mohammadi G; Saniee L; Mousaviagdas M; Chavoshi H; Tavassoli A
Asian Pac J Cancer Prev; 2015; 16(15):6749-51. PubMed ID: 26434905
[TBL] [Abstract][Full Text] [Related]
73. Arachidonate 5 lipoxygenase expression in papillary thyroid carcinoma promotes invasion via MMP-9 induction.
Kummer NT; Nowicki TS; Azzi JP; Reyes I; Iacob C; Xie S; Swati I; Darzynkiewicz Z; Gotlinger KH; Suslina N; Schantz S; Tiwari RK; Geliebter J
J Cell Biochem; 2012 Jun; 113(6):1998-2008. PubMed ID: 22253131
[TBL] [Abstract][Full Text] [Related]
74. Serum ghrelin levels in papillary thyroid carcinoma.
Ucan B; Sahin M; Kizilgul M; Ozbek M; Ozdemir S; Calıskan M; Cakal E
Arch Endocrinol Metab; 2017; 61(5):464-469. PubMed ID: 28977162
[TBL] [Abstract][Full Text] [Related]
75. [Serous-papillary carcinoma of the uterus].
Kolles H; von Seebach HB; Depper H; Loskant G
Pathologe; 1990 Sep; 11(5):295-8. PubMed ID: 2263566
[No Abstract] [Full Text] [Related]
76. Serum ferritin in thyroid cancer.
Deshpande UR; Nadkarni GD; Samuel AM
Thyroid; 1993; 3(4):301-3. PubMed ID: 8118224
[TBL] [Abstract][Full Text] [Related]
77. Matrix metalloproteinases: promoters of tumor progression and invasiveness.
Sela BA
Isr Med Assoc J; 2002 Apr; 4(4):280-2. PubMed ID: 12001703
[No Abstract] [Full Text] [Related]
78. Size of primary tumour and occurrence and weight of regional lymph gland metastases in thyroid gland carcinoma in various age groups.
Sivula A
Acta Chir Scand; 1971; 137(3):209-12. PubMed ID: 5149076
[No Abstract] [Full Text] [Related]
79. Significance of autotaxin activity and overexpression in comparison to soluble intercellular adhesion molecule in thyroid cancer.
Hassan AM; Alm El-Din MA; Nagy H; Ghoneem N; El-Heniedy MA; Koteb N; El-Gohary S
Int J Biol Markers; 2013 Apr; 28(1):84-91. PubMed ID: 23558934
[TBL] [Abstract][Full Text] [Related]
80. Clinical value of matrix metalloproteinase-2 and -9 in ultrasound-guided radiofrequency ablation treatment for papillary thyroid carcinoma.
Pan Q; Yuan T; Ding Q
J Int Med Res; 2020 Aug; 48(8):300060520917581. PubMed ID: 32772889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
